⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28571213 | 0.97 | CTSS (0.35) | — | |
| SCHEMBL22047390 | 0.79 | — | — | |
| SCHEMBL15114005 | 0.79 | — | — | |
| SCHEMBL145205 | 0.77 | — | — | |
| SCHEMBL21028209 | 0.77 | CTSS (0.34) | — | |
| SCHEMBL24567794 | 0.77 | CTSS (0.34) | — | |
| SCHEMBL194478 | 0.77 | — | — | |
| SCHEMBL17356271 | 0.77 | — | — | |
| SCHEMBL19091095 | 0.77 | — | — | |
| SCHEMBL24875185 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA BV (NL) | 2025-11-27 | — | — | US | disclosed |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2024-10-10 | — | — | US | disclosed |
| WO-2024035771-A2 | ULK3 INHIBITORS AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-3870576-B1 | BEZOPYRAZOLE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7396828-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| EP-0921800-B1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |